Idelalisib in Relapsed or Refractory Follicular Lymphoma

Idelalisib in Relapsed or Refractory Follicular Lymphoma

obr

2 weeks
9 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the results and findings for idelalisib in patients with relapsed or refractory follicular lymphoma.
Up Next Autoplay